Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
EMBO J ; 41(21): e110727, 2022 Nov 02.
Article in English | MEDLINE | ID: covidwho-2040455

ABSTRACT

Better understanding on interactions between SARS-CoV-2 and host cells should help to identify host factors that may be targetable to combat infection and COVID-19 pathology. To this end, we have conducted a genome-wide CRISPR/Cas9-based loss-of-function screen in human lung cancer cells infected with SARS-CoV-2-pseudotyped lentiviruses. Our results recapitulate many findings from previous screens that used full SARS-CoV-2 viruses, but also unveil two novel critical host factors: the lysosomal efflux transporter SPNS1 and the plasma and lysosomal membrane protein PLAC8. Functional experiments with full SARS-CoV-2 viruses confirm that loss-of-function of these genes impairs viral entry. We find that PLAC8 is a key limiting host factor, whose overexpression boosts viral infection in eight different human lung cancer cell lines. Using single-cell RNA-Seq data analyses, we demonstrate that PLAC8 is highly expressed in ciliated and secretory cells of the respiratory tract, as well as in gut enterocytes, cell types that are highly susceptible to SARS-CoV-2 infection. Proteomics and cell biology studies suggest that PLAC8 and SPNS1 regulate the autophagolysosomal compartment and affect the intracellular fate of endocytosed virions.


Subject(s)
COVID-19 , Lung Neoplasms , Humans , SARS-CoV-2 , Angiotensin-Converting Enzyme 2 , Lysosome-Associated Membrane Glycoproteins , Autophagy , Proteins
2.
Front Cell Infect Microbiol ; 12: 942951, 2022.
Article in English | MEDLINE | ID: covidwho-1987476

ABSTRACT

Coronavirus disease 19 (COVID-19) is a persistent global pandemic with a very heterogeneous disease presentation ranging from a mild disease to dismal prognosis. Early detection of sensitivity and severity of COVID-19 is essential for the development of new treatments. In the present study, we measured the levels of circulating growth differentiation factor 15 (GDF15) and angiotensin-converting enzyme 2 (ACE2) in plasma of severity-stratified COVID-19 patients and uninfected control patients and characterized the in vitro effects and cohort frequency of ACE2 SNPs. Our results show that while circulating GDF15 and ACE2 stratify COVID-19 patients according to disease severity, ACE2 missense SNPs constitute a risk factor linked to infection susceptibility.


Subject(s)
Angiotensin-Converting Enzyme 2/genetics , COVID-19 , Angiotensin-Converting Enzyme 2/metabolism , COVID-19/diagnosis , Growth Differentiation Factor 15/genetics , Humans , Mutation , Peptidyl-Dipeptidase A/genetics , SARS-CoV-2/genetics
SELECTION OF CITATIONS
SEARCH DETAIL